Arcus Biosciences (RCUS) EBIT: 2017-2025
Historic EBIT for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to -$142.0 million.
- Arcus Biosciences' EBIT fell 35.24% to -$142.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$375.0 million, marking a year-over-year decrease of 17.92%. This contributed to the annual value of -$330.0 million for FY2024, which is 2.94% up from last year.
- According to the latest figures from Q3 2025, Arcus Biosciences' EBIT is -$142.0 million, which was down 1,675.00% from -$8.0 million recorded in Q2 2025.
- Over the past 5 years, Arcus Biosciences' EBIT peaked at $281.0 million during Q4 2021, and registered a low of -$142.0 million during Q3 2025.
- For the 3-year period, Arcus Biosciences' EBIT averaged around -$85.6 million, with its median value being -$91.0 million (2023).
- Data for Arcus Biosciences' EBIT shows a peak YoY increase of 642.75% (in 2021) and a maximum YoY decrease of 5,134.54% (in 2021) over the last 5 years.
- Quarterly analysis of 5 years shows Arcus Biosciences' EBIT stood at $281.0 million in 2021, then tumbled by 126.33% to -$74.0 million in 2022, then fell by 22.97% to -$91.0 million in 2023, then decreased by 13.19% to -$103.0 million in 2024, then tumbled by 35.24% to -$142.0 million in 2025.
- Its EBIT was -$142.0 million in Q3 2025, compared to -$8.0 million in Q2 2025 and -$122.0 million in Q1 2025.